CAJ | 학술논문

目的：探讨阿立哌唑与利培酮治疗脑血管疾病所致精神障碍的临床疗效及安全性。方法将20例脑血管疾病所致精神障碍患者随机分为两组，分别予以阿立哌唑和利培酮治疗，观察6周。于治疗前后采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表评分较治疗前显著降低（P＜0．01），同期两组间比较差异无显著性（P＞0．05）；阿立哌唑组不良发应发生率低于利培酮组，但差异无显著性（P＞0．05）。结论阿立哌唑治疗脑血管疾病所致精神障碍疗效显著，与利培酮相当，但安全性更高。
목적：탐토아립고서여리배동치료뇌혈관질병소치정신장애적림상료효급안전성。방법장20례뇌혈관질병소치정신장애환자수궤분위량조，분별여이아립고서화리배동치료，관찰6주。우치료전후채용양성여음성증상량표평정림상료효，부반응량표평정불량반응。결과치료후량조양성여음성증상량표평분교치료전현저강저（P＜0．01），동기량조간비교차이무현저성（P＞0．05）；아립고서조불량발응발생솔저우리배동조，단차이무현저성（P＞0．05）。결론아립고서치료뇌혈관질병소치정신장애료효현저，여리배동상당，단안전성경고。
Objective To explore the efficacy and safely of aripiprazole and ris‐peridone in the treatment of mental disorders due to cerebrovascular disease (MD‐CD) . Methods Twenty 20 MDCD patients were randomly assigned to two groups and treated with aripiprazole or risperidone for 6 weeks .Efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results After treatment the PANSS scores of both groups lowered more significantly compared with pretreatment (P<0 .01) .Contemporane‐ous group comparisons showed no significant differences (P>0 .05);the incidence of adverse reactions was lower in aripiprazole than risperidone group ,but difference wasn’t significant (P>0 .05) .Conclusion Aripiprazole equivalent to risperidone has an evident effect in the treatment of MDCD ,but aripiprazole’s safety is higher .